Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ABVC

ABVC BioPharma Inc

Dec 11 • 04:00PM ET

0.5198

Dollar change +0.0451
Percentage change 9.50	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN VRTX REGN GILD BIIB MRNA BMY PFE JNJ LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	14.84%	Shs Outstand	12.71M	Perf Week	-4.97%
Market Cap	6.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	11.05M	Perf Month	-1.20%
Income	-8.24M	PEG	-	EPS next Q	-	Inst Own	1.76%	Short Float	2.29%	Perf Quarter	-24.69%
Sales	0.51M	P/S	13.23	EPS this Y	-	Inst Trans	227.09%	Short Ratio	1.68	Perf Half Y	-39.40%
Book/sh	0.66	P/B	0.79	EPS next Y	-	ROA	-51.96%	Short Interest	0.25M	Perf Year	-50.50%
Cash/sh	0.06	P/C	8.03	EPS next 5Y	-	ROE	-90.91%	52W Range	0.41 - 2.45	Perf YTD	-55.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.78%	ROI	-96.97%	52W High	-78.78%	Beta	0.75
Dividend TTM	-	Quick Ratio	0.34	Sales past 5Y	2003.75%	Gross Margin	66.82%	52W Low	28.25%	ATR (14)	0.05
Dividend Ex-Date	Sep 16, 2013	Current Ratio	0.34	EPS Y/Y TTM	74.62%	Oper. Margin	-1242.22%	RSI (14)	46.44	Volatility	9.81% 8.22%
Employees	19	Debt/Eq	0.33	Sales Y/Y TTM	-31.04%	Profit Margin	-1616.97%	Recom	3.00	Target Price	20.20
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	98.17%	Payout	-	Rel Volume	35.19	Prev Close	0.47
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	2350.74%	Earnings	-	Avg Volume	150.68K	Price	0.52
SMA20	-1.01%	SMA50	-7.75%	SMA200	-37.33%	Trades		Volume	5,302,898	Change	9.50%

Today 06:30AM	ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners (GlobeNewswire) +9.50%
Nov-14-24 09:00AM	ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones (GlobeNewswire)
Oct-22-24 08:45AM	ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners (GlobeNewswire)
Aug-15-24 07:30AM	ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements (GlobeNewswire) -5.19%
Jul-18-24 10:31AM	ABVC BioPharma's CEO Discusses New Drug Development and AI Integration (News Direct)
07:16AM	Loading…
Jul-09-24 07:16AM	ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI (NewMediaWire)
Jul-02-24 09:00AM	ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals (NewMediaWire) -8.16%
Jun-25-24 09:00AM	ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market (NewMediaWire)
Jun-12-24 09:20AM	ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue (NewMediaWire)
May-24-24 09:00AM	Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M (NewMediaWire) -9.09%
May-22-24 09:00AM	ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M (NewMediaWire)
May-17-24 10:52PM	ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024 (InvestorPlace)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
09:25AM	Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M (NewMediaWire)
May-09-24 09:35AM	Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M (NewMediaWire)
09:25AM	Loading…
Apr-18-24 09:25AM	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share (GlobeNewswire)
Apr-17-24 09:00AM	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M (GlobeNewswire) -8.93%
Apr-10-24 08:30AM	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M (GlobeNewswire)
Mar-26-24 08:30AM	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M (GlobeNewswire) +21.90%
Mar-21-24 08:30AM	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars (GlobeNewswire)
Mar-19-24 08:30AM	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine (GlobeNewswire)
Mar-14-24 09:30AM	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update (GlobeNewswire)
Feb-27-24 08:30AM	ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars (GlobeNewswire)
Feb-15-24 08:30AM	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues (GlobeNewswire)
Feb-12-24 08:30AM	ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Feb-08-24 09:17AM	ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share (GlobeNewswire) -7.14%
Jan-03-24 07:24AM	ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees (GlobeNewswire) +60.83%
Dec-07-23 08:30AM	ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.41%
Dec-05-23 08:30AM	ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials (GlobeNewswire)
Nov-21-23 08:30AM	ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market (GlobeNewswire) +5.33%
10:05AM	Loading…
Nov-16-23 10:05AM	ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M (GlobeNewswire) +27.20%
Nov-15-23 09:00AM	ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire) +11.61%
Oct-26-23 08:30AM	ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million (GlobeNewswire) +50.59%
Oct-17-23 08:30AM	ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.00%
Oct-09-23 08:30AM	ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Aug-23-23 08:30AM	ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study (GlobeNewswire)
Aug-17-23 09:19AM	ABVC Executes Cooperation Agreement for Strategic Investments (GlobeNewswire) -7.22%
Aug-10-23 08:30AM	ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -8.82%
Aug-07-23 08:30AM	ABVC Corporate Update and CEO's Letter to Shareholders (GlobeNewswire) -5.47%
Aug-03-23 09:20AM	ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration (GlobeNewswire)
Aug-01-23 08:30AM	ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales (GlobeNewswire) +44.98%
Jul-31-23 09:30AM	ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering (GlobeNewswire) -7.43%
Jul-27-23 09:22AM	ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering (GlobeNewswire) -41.73%
Jul-26-23 08:30AM	ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments (GlobeNewswire) +40.00%
Jul-24-23 12:30PM	ABVC BioPharma Announces Reverse Stock Split (GlobeNewswire)
Jul-06-23 08:30AM	The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency (GlobeNewswire) -6.49%
Jun-26-23 08:30AM	ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth (GlobeNewswire) +7.54%
Jun-20-23 08:30AM	ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production (GlobeNewswire) +7.90%
Jun-12-23 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF (GlobeNewswire)
Jun-06-23 08:30AM	ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization (GlobeNewswire)
May-22-23 08:30AM	ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia (GlobeNewswire) -5.42%
May-04-23 08:30AM	ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Apr-26-23 08:30AM	ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF (GlobeNewswire)
Apr-10-23 08:30AM	ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) (GlobeNewswire)
Apr-06-23 08:30AM	ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand (GlobeNewswire)
Mar-31-23 06:49PM	ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results (GlobeNewswire)
Mar-20-23 07:00AM	ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand (PR Newswire) +8.32%
Mar-14-23 07:00AM	ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare (PR Newswire) +11.21%
Feb-28-23 08:30AM	ABVC BioPharma Provides 2023 Pipeline Update (GlobeNewswire)
Feb-23-23 04:16PM	ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials (GlobeNewswire)
Feb-21-23 08:30AM	ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® (GlobeNewswire) +6.21%
Jan-19-23 08:30AM	ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference (GlobeNewswire)
Jan-18-23 08:25AM	ABVC: Several Potential Paths to Achieving Near-Term Milestones (Zacks Small Cap Research) -6.04%
Jan-05-23 08:30AM	FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer (GlobeNewswire) +72.58%
Dec-20-22 11:05AM	ABVC: Key Medical Venues Participating in Clinical Studies (Zacks Small Cap Research)
Nov-17-22 08:30AM	ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval (GlobeNewswire)
05:16AM	ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 06:20PM	ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results (GlobeNewswire)
Nov-07-22 08:30AM	ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) (GlobeNewswire)
Nov-02-22 08:30AM	Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharmas Medication for Treating Depression in Cancer Patients (GlobeNewswire)
Oct-05-22 08:30AM	ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia (GlobeNewswire)
Sep-23-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval (GlobeNewswire) +12.72%
Sep-16-22 09:36AM	ABVC: Moving Lead Assets Forward and Expanding Development Pipeline (Zacks Small Cap Research) -27.00%
Sep-13-22 08:30AM	ABVC Biopharma Announces Letter to Shareholders (GlobeNewswire)
Sep-09-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Site (GlobeNewswire)
Aug-22-22 08:30AM	ABVC Provides Oncology Pipeline Updates (GlobeNewswire)
Aug-18-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire) +19.62%
Aug-15-22 05:48PM	ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.76% +7.11%
Aug-02-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jul-18-22 08:30AM	ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028 (GlobeNewswire)
Jul-13-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update (GlobeNewswire)
Jul-06-22 08:30AM	Zacks Places Share Value of ABVC BioPharma at $9.50 (GlobeNewswire)
Jun-30-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire)
Jun-21-22 08:30AM	ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation (GlobeNewswire)
Jun-16-22 08:30AM	ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC (GlobeNewswire)
Jun-10-22 08:30AM	ABVC BioPharma Announces Termination of Two Contracts (GlobeNewswire) -47.37%
Jun-07-22 01:10PM	ABVC: Enrollment in ABV-1505 Part 2 ADHD Clinical Study Continues; First Patient Begins Treatment (Zacks Small Cap Research)
Jun-01-22 08:30AM	ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
May-25-22 08:30AM	ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners (GlobeNewswire)
May-23-22 07:30AM	Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines (GlobeNewswire)
May-16-22 05:46PM	ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.78%
03:25PM	WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire)
May-13-22 08:30AM	ABVC BioPharma Engages the FreeMind Group to Support Grant Funding (GlobeNewswire) +6.13%
May-12-22 09:00AM	WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering (PR Newswire) -13.47%
08:30AM	ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering (GlobeNewswire)
May-10-22 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated (GlobeNewswire) +8.24%
May-05-22 08:30AM	ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process (GlobeNewswire)
May-03-22 08:30AM	ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed (GlobeNewswire)
Apr-28-22 08:30AM	ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study (GlobeNewswire)
Apr-26-22 08:30AM	ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting (GlobeNewswire)

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVC

ABVC BioPharma Inc

Upgrade your FINVIZ experience